Clear Street says Oruka Therapeutics (ORKA)’ data for ORKA-001 hit the “bull case.” Initial data from the Phase 1 healthy volunteer trial for ORKA-001 revealed an “impressive” 100-day half-life, surpassing the 75-day threshold required for a once a year dosing schedule, the analyst tells investors in a research note. The firm believes the data indicate ORKA-001 is a “formidable contender” in the $25B plaque psoriasis market. It keeps a Buy rating on Oruka Therapeutics with a $46 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics sells 10.9M shares at $15 in private placement
- Oruka Therapeutics announces interim data from ORKA-001 trial at EADV
- Oruka Therapeutics initiated with a Buy at Clear Street
- Oruka Therapeutics: Promising Clinical Developments and Strong Financial Health Justify Buy Rating
- Promising Prospects for Oruka Therapeutics: Buy Rating Backed by Strong Growth and Financial Stability